Omada Health (OMDA) Q2 2026 earnings review
Record Profitability Overshadows Massive Concentration Risk and CEO Transition
Omada Health delivered a blowout second quarter, with revenue growing 43% YoY to $88 million and Adjusted EBITDA rocketing to a record $11 million. Operating leverage is firmly taking hold, allowing management to significantly raise full-year revenue and profit guidance. However, two major developments complicate the bullish financial narrative: co-founder Sean Duffy is stepping down as CEO at the end of the year, and an alarming spike in Accounts Receivable is entirely driven by a single related party that now accounts for nearly 64% of all Services revenue.
🐂 Bull Case
Gross margins expanded to an all-time high of 73% (up 700 bps YoY), driving $11M in Adjusted EBITDA. The company's AI initiatives and care-team optimization have permanently altered its unit economics.
The HCSC expansion (adding 1.5 million lives) and a new cholesterol program for a major retailer prove Omada's ability to cross-sell beyond its core diabetes and GLP-1 weight health offerings.
🐻 Bear Case
Over 63% of Services revenue ($51.4M of $80.7M) in Q2 came from a single undisclosed related party. This introduces massive, singular counterparty risk to the top line.
Total Accounts Receivable spiked 63% sequentially from Dec 31, 2025. This was almost entirely driven by the related party, whose outstanding balance jumped from $22.8M to $40.4M, suggesting potential collections or payment timing issues.
⚖️ Verdict: ⚪
Neutral. While the headline operating leverage and raised guidance are spectacular, a leadership change combined with a skyrocketing related-party receivables balance requires extreme investor caution until the nature of this related party is fully transparent.
Key Themes
Ballooning Related-Party Concentration and AR Spike
The most critical data point in this report is buried in the balance sheet footnotes. Accounts Receivable spiked from $34.6M at year-end to $56.6M in Q2. Alarmingly, $40.4M (71%) of this outstanding balance belongs to a single related party. This same related party accounted for $51.4M in Services revenue this quarter, meaning 63.7% of Omada's core service revenue is tethered to one entity. This trend is Reversing negatively, as the related party share was only 64.1% a year ago, but the raw dollar exposure has grown by $14.9M YoY.
AI and Care Team Operating Leverage
AI adoption (specifically tools like OmadaSpark and Meal Map) is proving to be a structural tailwind for margins. Adjusted EBITDA margin accelerated to 12% in Q2 2026, up from effectively 0% a year ago. Management's thesis that they can decouple revenue growth (43%) from care team headcount growth is being validated by 74% non-GAAP gross margins.
Integrated Platform Cross-Selling
Omada is successfully combatting 'point solution fatigue' in the macro healthcare landscape. The expansion with Health Care Services Corporation (HCSC) pushed the Prevention & Weight Health and Hypertension Management programs across 1.5 million newly covered lives in Illinois, Oklahoma, and New Mexico. Multi-condition adoption is Accelerating.
CEO Transition During Critical Growth Phase
Co-founder Sean Duffy will transition to Executive Chair in January 2027, handing the CEO role to President Wei-Li Shao. While Shao has effectively managed the P&L since 2021, changing leadership while navigating massive scale-up requirements, PBM vendor consolidation, and intense GLP-1 competition introduces execution risk.
Prescribing Revenue Pushed to 2027
The highly anticipated GLP-1 prescribing program secured its first customer. However, management noted this will only yield revenue starting in 2027. While it validates market demand, the immediate financial impact of this new strategic pillar remains a distant catalyst, requiring investors to wait for meaningful contribution.
Hardware Revenue Outpacing Gross Margins on Devices
Hardware revenue grew 62% YoY to $7.1M, outpacing Services growth. However, hardware cost of revenue was $10.4M, resulting in a negative hardware gross margin. As member growth is Accelerating (up 45%), the upfront cost of shipping connected devices continues to act as a drag on overall profitability, despite software efficiencies.
Other KPIs
Accelerating dramatically. With $80.7M in services revenue against only $13.6M in services costs, the underlying software and coaching engine is achieving SaaS-like gross margins. This provides massive leeway to absorb the loss-leading hardware deployments.
Stable. The trailing twelve-month revenue per total member grew approximately 2% YoY. As new members flood in (diluting initial ARPU) and mature members step down in pricing tier, maintaining flat-to-slightly-up ARPU is a positive indicator that cross-selling (like the new Cholesterol program) is offsetting natural maturation decay.
Guidance
Accelerating. The midpoint of $337M represents 30% YoY growth. This is a robust raise from the prior outlook of $322-$330M, indicating that Q2's outperformance is structural and pipeline conversion for H2 remains highly visible.
Accelerating. The new midpoint of $24M is a massive upward revision from the prior $14-$20M range, and represents a 4x increase over 2025's $6M result. This confirms that incremental revenue is dropping directly to the bottom line at an elevated rate.
Key Questions
Related Party Exposure
Over 63% of your Q2 services revenue and $40.4M of your Accounts Receivable is tied to a single related party. Can you disclose the nature of this relationship and explain the sequential spike in uncollected receivables?
Hardware Margin Drag
Hardware cost of revenue was $10.4M against $7.1M in hardware revenue. As we scale towards 1.5 million+ members, what initiatives are in place to reduce unit hardware costs or shift more cost burden to the employer?
Prescribing Program Economics
You announced your first prescribing program customer will generate revenue in 2027. Given this involves clinical evaluation and physician networks, how does the gross margin profile of this revenue compare to your traditional coaching programs?
CEO Transition Strategy
With Sean Duffy transitioning to Executive Chair in 2027, how will the division of labor between him and Wei-Li Shao evolve regarding M&A strategy, capital allocation, and product vision over the next 18 months?